Evidence map›Paper›PMID 41286042›Full record

Observational studyScientific reports2025

Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study.

Yudai Harimitsu, Toshinobu Hayashi, Mototsugu Shimokawa, Takanori Miyoshi, Akari Yamashita, Masanobu Uchiyama, Soichiro Ushio, Chihiro Shiraishi, Koichi Matsuo, Takashi Egawa

Abstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yudai Harimitsu *Department of Pharmacy, National Hospital Organization Kyushu Medical Center, 1-8-1, Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan.
Toshinobu Hayashi *Department of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. toshinobu@fukuoka-u.ac.jp.ORCID 0000-0001-6183-4939
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1, Minamiogushi, Ube, Yamaguchi, 755-8505, Japan. moto@yamaguchi-u.ac.jp.
Takanori MiyoshiDepartment of Pharmacy, National Hospital Organization Kyushu Medical Center, 1-8-1, Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan.
Akari YamashitaDepartment of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Masanobu UchiyamaDepartment of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Soichiro UshioDepartment of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Chihiro ShiraishiDepartment of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Koichi MatsuoDepartment of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Takashi EgawaDepartment of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin (cis-diamminedichloroplatinum [CDDP]) is a widely used anticancer drug with a significant risk of nephrotoxicity. This study aimed to compare the nephroprotective effects of mannitol and furosemide as forced diuretics in patients receiving CDDP-based chemotherapy. This multicenter retrospective study analyzed 472 patients with cancer receiving CDDP (≥ 60 mg/m

Indexed as

Antineoplastic AgentsCisplatinDiureticsFurosemideKidney DiseasesMannitolAdultAgedCreatinineFemaleHumansMaleMiddle AgedNeoplasmsRetrospective StudiesAntineoplastic AgentsCisplatinCreatinineDiureticsFurosemideMannitolAcute kidney injuryCisplatinForced diureticFurosemideMannitolNephrotoxicity

Identifiers

PMID41286042
PMCPMC12644863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.